On Monday, AN2 Therapeutics Inc (NASDAQ: ANTX) opened higher 11.11% from the last session, before settling in for the closing price of $1.26. Price fluctuations for ANTX have ranged from $0.87 to $22.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 37.08% at the time writing. With a float of $21.04 million, this company’s outstanding shares have now reached $29.87 million.
The firm has a total of 41 workers. Let’s measure their productivity. In terms of profitability, gross margin is 50.0%, operating margin of -83756.25%, and the pretax margin is -75871.25%.
AN2 Therapeutics Inc (ANTX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of AN2 Therapeutics Inc is 29.60%, while institutional ownership is 40.02%. The most recent insider transaction that took place on Dec 09 ’24, was worth 43,984. In this transaction Director of this company bought 30,772 shares at a rate of $1.43, taking the stock ownership to the 647,573 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Director bought 19,228 for $1.45, making the entire transaction worth $27,795. This insider now owns 629,090 shares in total.
AN2 Therapeutics Inc (ANTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.08% per share during the next fiscal year.
AN2 Therapeutics Inc (NASDAQ: ANTX) Trading Performance Indicators
Check out the current performance indicators for AN2 Therapeutics Inc (ANTX). In the past quarter, the stock posted a quick ratio of 9.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of AN2 Therapeutics Inc (ANTX)
Analysing the last 5-days average volume posted by the [AN2 Therapeutics Inc, ANTX], we can find that recorded value of 0.23 million was lower than the volume posted last year of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 22.22%. Additionally, its Average True Range was 0.09.
During the past 100 days, AN2 Therapeutics Inc’s (ANTX) raw stochastic average was set at 28.96%, which indicates a significant decrease from 47.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.30% in the past 14 days, which was lower than the 162.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2248, while its 200-day Moving Average is $1.8761. Now, the first resistance to watch is $1.4667. This is followed by the second major resistance level at $1.5333. The third major resistance level sits at $1.6367. If the price goes on to break the first support level at $1.2967, it is likely to go to the next support level at $1.1933. Should the price break the second support level, the third support level stands at $1.1267.
AN2 Therapeutics Inc (NASDAQ: ANTX) Key Stats
There are currently 29,879K shares outstanding in the company with a market cap of 41.50 million. Presently, the company’s annual sales total 0 K according to its annual income of -64,730 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -12,750 K.
